GPRC6A’s unique regulation of β-cell, skeletal muscle and hepatic function may represent a new therapeutic target for treating disordered energy metabolism metabolic syndrome and type 2 diabetes. The gene discussed is GPRC6A; the disease is type 2 diabetes mellitus.